A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer

Inclusion Criteria

• •1. Phase 1: Any incurable solid malignancy, with no more than 3 prior systemic treatment regimens.
• •Phase 2: Histologic diagnosis of advanced NSCLC, Stage IIIB with malignant pleural effusion or Stage IV per American Joint Committee on Cancer Staging Criteria for NSCLC. Participants must have failed 1 or 2 prior systemic treatment regimen(s).
• •2. Performance status of 0, 1, or 2 on the Eastern Cooperative Oncology Group (ECOG) Scale
• •3. Prior chemotherapy must be completed at least 2 weeks prior to study enrollment, and the participant must have recovered from acute toxic effects (except alopecia) prior to enrollment.
• •4. Prior radiotherapy is allowed to \<25% of the bone marrow. Prior radiotherapy must be completed at least 2 weeks before study enrollment, and the participant must have recovered from acute toxic effects (except alopecia) prior to enrollment.
• •5. Non-measurable or measurable disease as defined by Response Evaluation Criteria in Solid Tumors \[RECIST, version (v) 1.0\].